Catalyst
Slingshot members are tracking this event:
Top-line Phase 3b Data Released From Novo Nordisk's (NVO) SWITCH-2 Trial Evaluating Tresiba Versus Insulin Glargine in Type 2 Diabetes Patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 29, 2016
Related Projects
- Understanding the potential of Novo Nordisk's (NVO) Tresiba in treatment of type 2 diabetes NVO Execute By: Feb 05, 2016
Related Keywords
Type 2 Diabetes, Tresiba, Insulin Glargine, Switch-2 Trial, Hypoglycemic Events
